Skip to content
HowShorted

INmune Bio Inc. short interest in 2024

In 2024, INmune Bio Inc.'s disclosed short interest ran from 6.29% of shares outstanding on 12 Jan 2024 to 19.30% on 31 Dec 2024, a change of +13.01 percentage points. The year's high was 19.30% on 31 Dec 2024 and its low 6.29% on 12 Jan 2024, averaging 12.00% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.19 days on 31 May 2024. Full history: INmune Bio Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INmune Bio Inc. in 2024

2024 in figures

Start of year
6.29% (12 Jan 2024)
End of year
19.30% (31 Dec 2024)
Change
+13.01 pp
High
19.30% (31 Dec 2024)
Low
6.29% (12 Jan 2024)
Average
12.00%
Highest days to cover
24.19 (31 May 2024)
SEC filings marked
8

Every report in 2024

INmune Bio Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20246.29%11.41
31 Jan 20246.51%17.17
15 Feb 20246.52%13.33
29 Feb 20247.74%16.69
15 Mar 20248.01%23.43
28 Mar 20248.47%21.5110-K filed
15 Apr 20248.33%11.84results (8-K)
30 Apr 20249.61%8.40
15 May 20249.69%14.6910-Q filed, results (8-K)
31 May 20249.59%24.19
14 Jun 202410.08%23.53
28 Jun 202410.81%5.54
15 Jul 202413.75%19.43
31 Jul 202413.65%21.84
15 Aug 202414.03%16.4010-Q filed, results (8-K)
30 Aug 202415.25%16.20
13 Sep 202415.95%13.12
30 Sep 202413.56%6.74
15 Oct 202414.31%14.55
31 Oct 202415.71%12.8910-Q filed
15 Nov 202416.09%18.65results (8-K)
29 Nov 202416.72%21.51
13 Dec 202418.03%17.25
31 Dec 202419.30%19.18

See also: INmune Bio Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.